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Abstract
A major challenge in biomedical data science is to identify the causal genes underlying complex
genetic diseases. Despite the massive influx of genome sequencing data, identifying disease-relevant
genes remains difficult as individuals with the same disease may share very few, if any, genetic variants.
Protein-protein interaction networks provide a means to tackle this heterogeneity, as genes causing the
same disease tend to be proximal within networks. Previously, network propagation approaches have
spread “signal” across the network from either known disease genes or genes that are newly putatively
implicated in the disease (e.g., found to be mutated in exome studies or linked via genome-wide as-
sociation studies). Here we introduce a general framework that considers both sources of data within
a network context. Specifically, we use prior knowledge of disease-associated genes to guide random
walks initiated from genes that are newly identified as perhaps disease-relevant. In large-scale testing
across 24 cancer types, we demonstrate that our approach for integrating both prior and new information
not only better identifies cancer driver genes than using either source of information alone but also read-
ily outperforms other state-of-the-art network-based approaches. To demonstrate the versatility of our
approach, we also apply it to genome-wide association data to identify genes functionally relevant for
several complex diseases. Overall, our work suggests that guided network propagation approaches that
utilize both prior and new data are a powerful means to identify disease genes.
∗Department of Computer Science and Lewis-Sigler Institute for Integrative Genomics, Princeton University
†Email mona@cs.princeton.edu
ar
X
iv
:2
00
1.
06
13
5v
1 
 [q
-b
io.
GN
]  
17
 Ja
n 2
02
0
Introduction
Large-scale efforts such as the 1000 Genomes Project [1], The Cancer Genome Atlas (TCGA) [2], and
the Genome Aggregation Database [3], among others, have catalogued millions of variants occurring in
tens of thousands of healthy and disease genomes. Despite this abundance of genomic data, however, un-
derstanding the genetic basis underlying complex human diseases remains challenging [4]. In contrast to
simple Mendelian diseases, for which a small set of commonly shared genetic variants are responsible for
disease phenotypes, complex heterogeneous diseases are driven by a myriad of combinations of different
alterations. Individuals exhibiting the same phenotypic outcome—a particular disease—may share very few,
if any, genetic variants, thereby making it difficult to discover which of numerous variants are associated
with heterogeneous diseases, even when focusing just on changes that occur within genes.
Biological networks provide a powerful, unifying framework for identifying disease genes [5–8]. Genes
relevant for a given disease typically target a relatively small number of biological pathways, and since
genes that take part in the same pathway or process tend to be close to each other in networks [9, 10],
disease genes cluster within networks [11, 12]. Consequently, if genes known to be causal for a particular
disease are mapped onto a network, other disease-relevant genes are likely to be found in their vicinity [13].
Thus, the signal from known disease genes can be “propagated” across a network to prioritize either all genes
within the network or just candidate genes within a genomic locus where single nucleotide polymorphisms
have been correlated with an increased susceptibility to disease [14–19].
While initial network approaches to identify disease genes focused on propagating knowledge from a
set of known “gold standard” disease genes, with the widespread availability of cancer sequencing data and
genome-wide association studies (GWAS), the source of where information is propagated from has shifted
to genes that are newly identified as perhaps playing a role in disease [20–26]. For example, in the cancer
context, diffusing a signal from genes that are somatically mutated across tumors is highly effective for
identifying cancer-relevant genes and pathways [21, 25]; notably, while frequency-based approaches identify
genes that “drive” cancer by searching for those that are recurrently mutated across tumor samples beyond
some background rate [27], such a network propagation approach can even pinpoint rarely mutated driver
genes if they are within subnetworks whose component genes, when considered together, are frequently
mutated.
Thus there are two dominant network propagation paradigms for uncovering disease genes: spreading
signal either from well-established, annotated disease genes or from genes that have some new evidence
of being disease-relevant. While both have been successful independently, we argue that both sources of
information should be utilized together, and that existing knowledge of disease genes should inform the
way new data is examined within networks. That is, while our prior knowledge of causal genes for a
given disease may be incomplete, it nevertheless is a valuable source of information about the biological
processes underlying the disease; furthermore, in many cases, there is substantial prior knowledge and there
is no reason disease gene discovery should proceed de novo from newly observed alterations.
In this paper, we introduce a guided network propagation framework to uncover disease genes, where
signal is propagated from new data so as to tend to move towards genes that are closer to known disease
genes. Our core method of propagating information within a network is via either diffusion [28] or random
walks with restarts (RWRs) [14], as these are mathematically sound, well-established approaches, where nu-
merical solutions are easily obtained. In particular, our approach first diffuses a signal from known disease
genes, and then performs either guided random walks or guided diffusion from the new data so as to prefer-
entially move towards genes that have received higher amounts of signal from the initial set of known disease
genes. In contrast, previous network propagation methods for disease gene discovery have performed dif-
fusion or random walks uniformly from each node (i.e., in an “unguided” manner, as in e.g., [21, 24]), or
where the diffusion is scaled by weights on network edges that reflect their estimated reliabilities (e.g., [23]).
Alternatively, several approaches have attempted to uncover disease genes by explicitly connecting in the
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network genes that have genetic alterations with genes that have expression changes [29–34]; while well-
suited for finding genes causal for observed expression changes, such approaches are less appropriate as a
means to link prior and new information, and our approach instead uses prior knowledge to simply influence
information propagation within the network.
We demonstrate the efficacy of our method uKIN—using Knowledge In Networks—by first applying it
to discover genes causal for cancer. Here, new information consists of genes that are found to be somatically
mutated in tumors—only a small number of which are thought to play a functional role in cancer—and
prior information is comprised of subsets of “driver” genes known to be cancer-relevant [35]. In rigorous
large-scale, cross-validation style testing across 24 cancer types, we demonstrate that propagating signal
by integrating both these sources of information performs substantially better in uncovering known cancer
genes than propagating signal from either source alone. Notably, even using just a small number of known
cancer genes (5–20) to guide the network propagation from the set of mutated genes results in substantial
improvements over the unguided approach. Next, we compare uKIN to four state-of-the-art network-based
methods that use somatic mutation data for cancer gene discovery and find that uKIN readily outperforms
them, thereby demonstrating the advantage of additionally incorporating prior knowledge. We also show
that by using cancer-type specific prior knowledge, uKIN can better uncover causal genes for specific cancer
types. Finally, to showcase uKIN’s versatility, we show its effectiveness in identifying causal genes for
three other complex diseases, where the genes known to be associated with the disease come from the
Online Mendelian Inheritance in Man (OMIM) [36] and genes comprising the new information arise from
genome-wide association studies (GWAS).
Methods
Overview. At a high level, our approach uKIN propagates new information across a network, while using
prior information to guide this propagation (Figure 1). While our approach is generally applicable, here
we focus on the case of propagating information across biological networks in order to find disease genes.
We assume that prior knowledge about a disease consists of a set of genes already implicated as causal for
that disease, and new information consists of genes that are potentially disease-relevant. In the scenario of
uncovering cancer genes, prior information comes from the set of known cancer genes, and new information
corresponds to those genes that are found to be somatically mutated across patient tumors. For other complex
diseases, new information may arise from (say) genes weakly associated with a disease via GWAS studies
or found to have de novo or rare mutations in a patient population of interest.
The first step of our approach is to compute for each gene a measure that captures how close it is in
the network to the prior knowledge set of genes K (Figure 1a). To accomplish this, we spread the signal
from the genes in K using a diffusion kernel [28]. Next, we consider new information consisting of genes
M that have been identified as potentially being associated with the disease. As we expect those that are
actually disease-relevant to be proximal to each other and to the previously known set of disease genes, we
spread the signal from these newly implicated genesM, biasing the signal to move towards genes that are
closer to the known disease genes K (Figure 1b). We accomplish this by performing RWRs, where with
probability α, the walk jumps back to one of the genes inM. That is, α controls the extent to which we
use new versus prior information, where higher values of α weigh the new information more heavily. With
probability 1− α, the walk moves to a neighboring node, but instead of moving from one gene to one of its
neighbors uniformly at random as is typically done, the probability instead is higher for neighbors that are
closer to the prior knowledge set of genes K. Genes that are visited more frequently in these random walks
are more likely to be relevant for the disease because they are more likely to be part of important pathways
around K that are also close to M. We thus numerically compute the probability with which each gene
is visited in these random walks, and then use these probabilities to rank the genes. As an alternative to a
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RWR, we also experiment with implementing the guided propagation via a diffusion kernel [28]. Each step
of our procedure is described in more detail below.
Notation. The biologi-
Figure 1: Overview. (a) Known disease-relevant genes (prior knowledge) are
mapped onto an interaction network (shown in red, top). Signal from this prior
knowledge is propagated through the network via a diffusion approach [28], re-
sulting in each gene in the network being associated with a score such that higher
scores (visualized in darker shades of red, bottom) correspond to genes closer to
the set of known disease genes. These scores are used to set transition probabil-
ities between genes such that a neighboring gene that is closer to the set of prior
knowledge genes is more likely to be chosen. (b) Genes putatively associated
with the disease—corresponding to the new information—are mapped onto the
network (shown in green, top). To integrate both sources of information, RWRs
are initiated from the set of putatively associated genes, and at each step, the walk
either restarts or moves to a neighboring gene according to the transition proba-
bilities (i.e., walks tend to move towards genes outlined in darker shades of red).
These prior-knowledge “guided” RWRs have a stationary distribution correspond-
ing to how frequently each gene is visited, and this distribution is used to order
the genes. Higher scores correspond to more frequently visited genes (depicted in
darker greens, bottom).
cal network is modeled
as an undirected graph
G = (V,E) where each
vertex represents a gene,
and there is an edge be-
tween two vertices if an
interaction has been found
between the corresponding
protein products. We re-
quire G to be connected,
restricting ourselves to the
largest connected com-
ponent if necessary. We
explain our formulation
with respect to cancer,
but note that it is appli-
cable in other settings
(both disease and other-
wise). The set of genes
already known to be can-
cer associated is denoted
by K = {k1, k2, ..., kl}.
The set of genes that
have been found to be
somatically mutated in
a cohort of individuals
with cancer is denoted by
M = {m1,m2, ...,mp},
with F = {fm1 , fm2 , ..., fmp} corresponding to the rate with which each of these genes is mutated. We
refer to K as the prior knowledge andM as the new information. We assume that K ⊂ V andM ⊂ V ; in
practice, we remove genes not present in the network. The genes within K andM may overlap (i.e., it is
not required that K ∩M = ∅).
Guided RWR Algorithm. For each gene i ∈ V , assume that we have a measure qi that represents how close
i is to the set of genes K. We will use the nonnegative vector q, which we describe in the next section, to
guide a random walk starting at the nodes inM and walking towards the nodes in K. Each walk starts from
a gene i inM, chosen with probability proportional to its mutational rate fi. At each step, with probability
α the walk can restart from a gene inM, and with probability 1− α the walk moves to a neighboring gene
picked probabilistically based upon q. Specifically, if N (i) are the neighbors of node i, the walk goes from
node i to node j ∈ N (i) with probability proportional to qj/
∑
k∈N (i) qk. That is, if at time t the walk is at
node i, the probability that it transitions to node j at time t+ 1 is
pij = (1− α)δij · qj∑
k∈N(i) qk
+ α · fj∑
k∈M fk
where δij = 1 if j ∈ N (i) and 0 otherwise. Hence, the guided random walk is fully described by a
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stochastic transition matrix P with entries pij . By the Perron-Frobenius theorem, the corresponding random
walk has a stationary distribution pi (a left eigenvector of P associated with the eigenvalue 1). If the graph
G is connected, then the back edges toM easily ensure that pi is unique and can be approximated by a long
enough random walk. For each gene i, its score is given by the ith element of pi. The genes whose nodes
have high scores are most frequently visited and, therefore, are more likely relevant to cancer as they are
close to both the mutated starting nodes as well as to known cancer genes.
Incorporating prior knowledge. For each gene in the network, we wish to compute how close it is to
the set of cancer-associated genes K. While many approaches have been proposed to compute “distances”
in networks, we use a network flow/diffusion technique where each node k ∈ K introduces a continuous
unitary flow which diffuses uniformly across the edges of the graph and is lost from each node v ∈ V in
the graph at a constant first-order rate λ [28]. Briefly, let A = (aij) denote the adjacency matrix of G (i.e.,
aij = 1 if (i, j) ∈ E and 0 otherwise) and let S be the diagonal matrix where sii is the degree of node
i ∈ V . Then, the Laplacian of the graph G shifted by λ is defined as L = S + λI − A. The equilibrium
distribution of fluid density on the graph is computed as q = L−1b [28], where b is the vector with 1 for the
nodes introducing the flow and 0 for the rest (i.e., bi = 1 if vi ∈ K and bi = 0 if vi /∈ K for ∀vi ∈ V ).
Note that L is diagonally dominant, hence nonsingular, for any λ ≥ 0. We set λ = 1 in our applications.
The vector q can be efficiently computed numerically. Thus, at equilibrium, each node i in the graph is
associated with a score qi which reflects how close it is to the nodes already marked as causal for cancer.
Guided diffusion. Instead of performing RWRs to propagate knowledge in a guided manner, it is also
possible to adapt the diffusion approach just outlined by letting A = (aij) be defined such that aij =
qj/
∑
k∈N (i) qk, and using A to compute L and the equilibrium density as above.
Data sources and pre-processing. We test uKIN on two protein-protein interaction networks: HPRD
(Release 9 041310) [37] and BioGrid (Release 3.2.99, physical interactions only) [38]. We pre-process
the networks as in [39]. Briefly, we remove all proteins with an unusually high number of interactions
(> 900 interactions, > 10 standard deviations away from the mean number of interactions). Additionally,
to remove spurious interactions, we remove those that have a Z-score normalized diffusion state distance
> 0.3 [40]. This leaves HPRD with 9,379 proteins and 36,638 interactions and BioGrid with 14,326 proteins
and 102,552 interactions.
We use level 3 cancer somatic mutation data from TCGA [2] for 24 cancer types (Supplemental Table 1).
For each cancer type, we process the data as previously described and exclude samples that are obvious
outliers with respect to their total number of mutated genes [39]. Our set of prior knowledge is constructed
from the 719 CGC genes that are labeled by COSMIC (version August 2018) as being causally implicated
in cancer [35]. For each cancer type, our new information consists of genes that have somatic missense or
nonsense mutations, and we compute the mutational frequency of a gene as the number of observed somatic
missense and nonsense mutations across tumors, divided by the number of amino acids in the encoded
protein.
We obtain 24, 28, and 63 genes associated with three complex diseases, age-related macular degenera-
tion (AMD), Amyotrophic lateral sclerosis (ALS) and epilepsy, respectively, from OMIM [36]. These genes
are used to construct the set of prior knowledge. For each disease, we form the set M by querying from the
GWAS database [41] the genes implicated for the disease and using the corresponding p-values to compute
the starting frequencies f . Specifically, for each disease, for each GWAS study i, if a gene j’s p-value is
pi,j , we set its frequency to log(pi,j)/
∑
k log(pi,k) and then for each gene average these frequencies over
the studies.
Performance evaluation. To evaluate our method in the context of cancer, we subdivide the CGC genes
that appear in our network into two subsets. We randomly draw from the CGCs 400 genes to form a setH of
positives that we aim to uncover. From the remaining 199 CGCs present in the network, we randomly draw
a fixed number l to represent the prior knowledge K and run our framework. As we consider an increasing
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number of most highly ranked genes, we compute the fraction that are in the set H of positives. All CGC
genes not in H are ignored in these calculations. Importantly, the genes in K which are used to guide the
network propagation are never used to evaluate the performance of uKIN. Note that this testing set up, which
measures performance on H, allows us to compare performance of uKIN when choosing prior knowledge
sets of different size l from the CGC genes not inH.
We also compute area under the precision-recall curves (AUPRCs). In this case, all CGC genes in H
are considered positives, all CGC genes not in H are neutral (ignored), and all other genes are negatives.
Though we expect that there are genes other than those already in the CGC that play a role in cancer, this
is a standard approach to judge performance (e.g., see [24]) as cancer genes should be highly ranked. To
focus on performance with respect to the top predictions, we compute AUPRCs using the top 100 predicted
genes. To better estimate AUPRCs and account for the randomness in sampling, we repeatedly draw (10
times) the set H and for each draw we sample the genes comprising the prior knowledge K 10 times. The
final AUPRC results from averaging the AUPRCs across all 100 runs.
We compare uKIN on the cancer datasets to the frequency-based method MutSigCV 2.0 [42] and four
network-based methods, DriverNet [30], Muffinn [43], nCOP[39] and HotNet2 [25]. All methods
are run on each of the 24 cancer types with their default parameters. Muffinn, nCOP and HotNet2
are run on the same network as uKIN, whereas MutSigCV does not use a network and DriverNet instead
uses an influence (i.e., functional interaction) graph and transcriptomic data (we use their default influence
graph and provide as input TCGA normalized expression data). Since uKIN uses a subset of CGCs as prior
knowledge, we ensure that all methods are evaluated with respect to the hidden sets H (i.e., of CGCs not
used by uKIN). Though we could just consider performance with respect to one hidden set, considering
multiple sets enables a better estimate of overall performance. For these comparisons, uKIN with α = 0.5
is run 100 times, as described above, with 20 randomly sampled genes comprising the prior knowledge, and
evaluation is performed with respect to the genes in the hidden sets. All methods’ AUPRCs are computed
using the same randomly sampled test sets H and averaged at the end. Since HotNet2 outputs a set of
predicted cancer-relevant genes and does not rank them, we cannot compute AUPRCs for it; instead we
compute precision and recall for its output with respect to the test sets H and compare to uKIN’s when
considering the same number of top scoring genes.
To evaluate our method in the context of the three complex diseases, we subdivide evenly the set of
OMIM genes associated with each disease into the prior knowledge set K and the set of positives H. As
with the cancer data, we do this repeatedly (100 times) and average AUPRCs at the end.
Results
We first apply our method uKIN to uncover cancer genes. Genes that have missense and nonsense somatic
mutations comprise the new information, and random walks start from these genes with probability propor-
tional to their mutation rates. We apply our approach to data from 24 cancer types, but showcase results
for glioblastoma multiforme (GBM). All results in the main paper use the HPRD protein-protein interaction
network [37], with results shown for BioGrid [38] in the Supplement.
uKIN successfully integrates prior knowledge and new information. We compare uKIN’s performance
when using both prior and new knowledge (RWRs with α = 0.5), to versions of uKIN using either only
new information (α = 1) or only prior information (α = 0). Briefly, we use 20 randomly drawn CGCs to
represent the prior knowledgeK and another 400 randomly drawn CGCs to be the hidden setH of unknown
cancer-relevant genes that we aim to uncover (see Performance evaluation for details). We repeat this
process 100 times, each time spreading signal using the diffusion approach [28] before performing RWRs
from the genes observed to be somatically mutated. For each run, we analyze the ranked list of genes output
by uKIN as we consider an increasing number of output genes, and average across runs the fraction that are
members of the hidden setH consisting of cancer driver genes.
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Figure 2: uKIN successfully integrates new information and prior knowledge. (a) We illustrate the effectiveness
of our approach uKIN on the GBM data set and the HPRD protein-protein interaction network using 20 randomly
drawn CGCs to represent the prior knowledge. We combine prior and new knowledge using a restart probability of
α = 0.5 (blue line). As we consider an increasing number of high scoring genes, we plot the fraction of these that
are part of the hidden set of CGCs. As baseline comparisons, we also consider versions of our approach where we
use only the new information (α = 1) and order genes by their mutational frequency (green line); where we use new
information to perform unguided random walks with α = 0.5 and order genes by their probabilities in the stationary
distribution of the walk (which uses new information but not prior information, purple line); and where we use only
prior information (α = 0) and order genes based on information propagated from the set of genes comprising our prior
knowledge (orange line). Integrating both prior and new sources of information results in better performance. (b) The
performance of uKIN when integrating information at α = 0.5 is compared to the three baseline cases where either
only prior information is used (α = 0, left) or when only new information is used (α = 1, right and unguided RWRs
with α = 0.5, middle). In all three panels, for each cancer type, we plot the log2 ratio of the AUPRC of uKIN with
guided RWRs with α = 0.5 to the AUPRC of the other approach. Across all 24 cancer types, using both sources of
information outperforms using just one source of information.
For α = 0.5, we observe that a large fraction of the top predicted genes using the GBM dataset are part
of the hidden set of known cancer genes (Figure 2a). At α = 1, our method completely ignores both the
network and the prior informationK and is equivalent to ordering the genes by their mutational frequencies.
The very top of the list output by uKIN when α = 1 consists of the most frequently mutated genes (in the
case of GBM, this includes TP53 and PTEN). As we consider an increasing number of genes, ordering them
by mutational frequency is clearly outperformed by uKIN with α = 0.5. At the other extreme with α = 0,
the starting locations and their mutational frequencies are ignored as the random walk is memoryless and the
stationary distribution depends only upon the propagated prior information q. As expected, performance is
considerably worse than when running uKIN with α = 0.5. Nevertheless, we observe that several CCGs are
found for α = 0; this is due to the fact that known cancer genes tend to cluster together in the network [20]
and our propagation technique ranks highly the genes close to the genes in K.
We also consider uKIN’s performance as compared to an unguided walk with the same restart prob-
ability α = 0.5. In this case, the walk selects a neighboring node to move to uniformly at random. The
stationary distribution that the walk converges to depends upon the starting locations and the network topol-
ogy but is independent of the prior information. Such a walk provides a good baseline to judge the impact
6
the propagated prior information q has on the performance of our algorithm, and is an approach that has
been widely applied [14]. As evident in Figure 2a, an unguided walk (purple line) performs considerably
worse than uKIN with α = 0.5, highlighting the importance of q in guiding the walk.
Notably, the trends we observe on GBM hold across all 24 cancers (Figure 2b). For each cancer type, we
consider the log2 ratio of the AUPRC of the version of uKIN that uses both prior and new information with
α = 0.5 to the AUPRC for each of the other variants. For all cancer 24 cancers, when uKIN uses both prior
and new information with α = 0.5, it outperforms the cases when using only prior information (Figure 2b,
left) or using only new information (Figure 2b, middle and right). Further, we observe this improvement
when using both prior and new information across all cancers for a wide range of α (0.2 < α < 0.8, data
not shown), clearly demonstrating that using both sources of information is beneficial.
uKIN is effective in uncovering cancer-relevant genes. We next evaluate uKIN’s performance in uncov-
ering cancer-relevant genes as compared to several previous methods. These methods do not use any prior
knowledge of cancer genes, and any performance differences between uKIN and them may be due either
to the use of this important additional source of information or to specific algorithmic differences between
the methods. Nevertheless, such comparisons are necessary to get an idea of how well uKIN performs
as compared to the current state-of-the-art. All methods are run and AUPRCs computed as described in
Methods. First, we compare uKIN with α = 0.5 to MutSigCV 2.0 [42], perhaps the most widely used
frequency-based approach to identify cancer driver genes. We find that uKIN outperforms MutSigCV 2.0
on 22 of 24 cancer types (Figure 3a). Next, we compare uKIN to three network-based approaches (Fig-
ure 3b): Muffinn [43], which considers mutations found in interacting genes; DriverNet [30], which
finds driver genes by uncovering sets of somatically mutated genes that are linked to dysregulated genes;
and nCOP [39], which examines the per-individual mutational profiles of cancer patients in a biological
network. uKIN exhibits superior performance across all cancer types when compared to DriverNet,
and outperforms Muffinn in 23 out of 24 cancer types and nCOP in 17 of the 24 cancer types. In many
cases, the performance improvements of uKIN are substantial (e.g., more than a 2-fold improvement for
12, 10, 3 and 4 cancer types for MutSigCV, DriverNet, Muffin and nCOP, respectively). We also
compare to Hotnet2 [25], whose core algorithmic component is diffusion [28], and as such uKIN is more
similar to it than other methods. Hotnet2 does not output a ranked list of genes, so we instead examine
the list of genes highlighted by both methods. We find that uKIN exhibits higher precision and recall than
Hotnet2 for all cancer types (Suppl. Figure S1); since both uKIN and Hotnet2 are network propagation
approaches, these performance improvements illustrate the benefit of using prior information in identifying
cancer-relevant genes.
Robustness tests. The overall results shown hold when we use different lists of known cancer genes as a
gold standard (Suppl. Figure S2a), different numbers of predictions considered when computing AUPRCs
(Suppl. Figure S2b), and different networks (Suppl. Figure S2c). Further, we confirm the importance of
network structure to uKIN, by running uKIN on two types of randomized networks, degree-preserving and
label shuffling, and show that, as expected, overall performance deteriorates across the cancer types (Suppl.
Figure S2d); we note that while network structure is destroyed by these randomizations, per-gene mutational
information is preserved, and thus highly mutated genes are still output.
We also determine the effect of the amount of prior knowledge for uKIN, and find that while perfor-
mance increases with larger numbers of genes comprising our prior knowledge, even as few as five prior
knowledge genes leads to a ∼4-fold improvement over ranking genes by mutational frequency (Suppl. Fig-
ure S3a). Finally, we investigate the effect of some incorrect prior knowledge, and find that while uKIN’s
performance decreases with more incorrect knowledge, uKIN with α = 0.5 performs reasonably with
< 20% incorrect annotations (Suppl. Figure S3b).
Alternate formulations. We also tested guided diffusion from the somatically mutated genes instead of
RWRs (see Methods). We empirically find that, for α = 0.5, diffusion with λ = 1 yields nearly identical
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per-gene scores on the cancer datasets we tested (GBM and kidney renal cell carcinoma). Similarly, for
other α, we were able to find values of λ such that the RWRs and diffusion have highly similar results. On
the other hand, replacing the initial diffusion from the prior knowledge with a RWR (with α = 0.5) results
in somewhat worse performance (e.g., ∼10% drop in AUPRC for GBM).
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Figure 3: uKIN is more effective than other methods in identifying known
cancer genes. For each method, for each cancer type, we plot the log2 ratio of
uKIN’s AUPRC to its AUPRC. (a) Comparison of uKIN to MutSigCV 2.0, a
state-of-the-art frequency-based approach. uKIN outperforms MutSigCV 2.0
on 22 of the 24 cancer types. (b) Comparison of uKIN to DriverNet
(left), Muffinn (middle), and nCOP (right). Our approach uKIN outperforms
DriverNet on all cancer types, Muffinn on all but one cancer type and nCOP
on 17 out of 24 cancer types.
quently mutated cancer-
relevant genes. A major
advantage of network-based
methods is that they are able
to identify cancer-relevant
genes that are not necessarily
mutated in large numbers of
patients [25]. We next ana-
lyze the mutation frequency
of genes output by uKIN
with α = 0.5. In particular,
for each cancer type, for each
gene, we obtain a final score
by averaging scores across
the 100 runs of uKIN; to pre-
vent “leakage” from the prior
knowledge set, if a gene is
in the set of prior knowledge
genes K for a run, this run is
not used when determining
its final score. We confirm
that, for all cancer types, the
top scoring genes exhibit
diverse mutational rates, and
include both frequently and infrequently mutated genes (Suppl. Figure S4).
We next highlight some infrequently mutated genes in GBM that are given high final scores by uKIN
(i.e., are predicted as cancer-relevant). For example, LAND1A and SMAD4 are two well known cancer
players that are highly ranked by uKIN, and that have mutational rates in GBM that are in the bottom 70%
of all genes and are therefore hard to detect with frequency-based approaches. Of uKIN’s top 100 scoring
genes, 23 are are in the bottom half with respect to mutational rates, and 5 of these are CGCs (p < 10−2,
hypergeometric test). When considering the top scoring 100 genes by uKIN for each cancer type, those
that have mutational ranks in the bottom half of all genes are each found to have a statistically significant
enrichments of CGC genes. Thus, uKIN provides a means for pulling out cancer genes from the “long
tail” [44] of infrequently mutated genes.
In addition to highlighting known cancer genes, uKIN also ranks highly several non-CGC genes that
may or may not play a functional role in cancer, as our knowledge of cancer-related genes is incomplete.
Among these novel predictions for GBM are ATXN1, SMURF1, and CCR3, all of which have been recently
suggested to play a role in cancers [45–47] and are each mutated in less than 5% of the samples. ATXN1 is
a chromatin-binding factor that plays a critical role in the development of spinocerebellar ataxia, a neurode-
generative disorder [48], and mutants of ATXN1 have been found to stimulate the proliferation of cerebellar
stem cells in mice [49]. This is a promising gene for further investigation because glioblastoma is a cancer
that usually starts in the cerebrum and the potential role of ATXN1 in tumorigenesis has only recently been
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suggested [45]. SMURF1 and its highly ranked by uKIN network-interactor SMAD1 have already been
implicated in the development of several cancers [50]. SMURF1 also interacts with the nuclear receptor
TLX whose inhibitory role in glioblastoma has been revealed [51]. Overall, we also find that the top scoring
genes by uKIN for GBM are enriched in many KEGG pathways and GO terms relevant for cancer, including
microRNAs in cancer, cell proliferation, choline metabolism in cancer and apoptosis (Bonferroni-corrected
p < 0.001, hypergeometric test).
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Figure 4: (a) Use of cancer-type specific knowledge improves performance.
For four cancer types, BRCA, GBM, SKCM, and THCA, we consider the perfor-
mance of uKIN with α = 0.5 when using TCGA mutational data for that cancer
type with prior knowledge consisting of genes known to be driver in that cancer
type, as compared to performance when the prior knowledge set consists of genes
that are annotated as driver only for one of the other three cancer types. For each
cancer, performance is measured by the average ranking by uKIN of genes known
to be driver for that cancer. For all combinations of possible prior knowledge sets
(x-axis) and specific cancer gene sets that we wish to recover (y-axis), using prior
knowledge from another cancer (off diagonal entries) leads to a decrease in perfor-
mance as compared to the corresponding pairs (diagonal entries), as measured by
the increase in uKIN’s average ranking of genes we aimed to uncover. (b) uKIN is
effective in identifying complex disease genes. We demonstrate the versatility of
the uKIN framework by integrating OMIM and GWAS data for three complex dis-
eases, ALS, epilepsy and AMD. For each disease, we compare uKIN’s performance
when using OMIM annotated genes as prior information and GWAS hits as new
information with α = 0.5, to baseline versions that propagate only information via
diffusion from OMIM (left) or GWAS studies (right). In all cases, we plot the log2
ratio of the AUPRC obtained by uKIN using both prior and new information to the
baseline methods.
knowledge yields better
performance. In several
cases, CGC genes are anno-
tated with the specific cancers
they play driver roles in. We
next test how uKIN’s perfor-
mance changes when using
such highly specific prior
knowledge. We consider
four cancer types, GBM,
breast invasive carcinoma
(BRCA), skin cutaneous
carcinoma (SKCM), and
thyroid carcinoma (THCA),
with 33, 32, 42 and 29 CGC
genes annotated to them,
respectively. We repeatedly
split each of these sets of
genes in half, and use half as
the set K of prior knowledge,
and the other half as the set
H to test performance.
We first use knowledge
consisting of genes specific to
a cancer type of interest to-
gether with the TCGA data
for that cancer to uncover
that cancer’s specific drivers.
Given the small number of
genes annotated to each cancer, we assess performance by, for each of these genes, computing the rank
of its score by uKIN over the splits where these genes are in H. Next, for the same cancer type, we use a
set K corresponding to a different cancer type as prior knowledge (excluding any genes that are annotated
to the original cancer type) while still trying to uncover the genes in the original cancer of interest (i.e.,
using TCGA mutational data and H belonging to the original cancer type). That is, we are testing the
performance of uKIN when using knowledge corresponding to a different cancer type. For all four cancer
types, we find that performance is best when uKIN uses prior knowledge for the same cancer cancer type
(Figure 4a), as genes in H appear higher in the list of genes output by uKIN. This suggests that uKIN can
utilize cancer-type specific knowledge and highlights the benefits of having accurate prior information.
Application to identify disease genes for complex inherited disorders. A major advantage of our method
is that it can be easily applied in diverse settings. As proof of concept, we apply uKIN to detect disease genes
9
for three complex diseases: AMD, ALS and epilepsy. For each disease, we randomly split in half the OMIM
database’s [36] list of genes associated with the disease 100 times to form the set of prior knowledge K and
the hidden set H. We use the GWAS catalogue list of genes with their corresponding p-values to form the
setM. For all three diseases, uKIN combining both GWAS and OMIM sources of information (α = 0.5)
performs better than diffusing the signal with λ = 1 using only knowledge from OMIM (Figure 4b, left
panel). For each of these diseases, there is virtually no overlap between the GWAS hits M and a set of
OMIM genes H; simply sorting genes by their significance in GWAS studies (i.e., uKIN with α = 1)
results in AUPRC of 0. Instead, we spread information from the set of GWAS genesM in the same fashion
as from OMIM and observe again that using this single source of information alone does not work as well
as uKIN’s using both GWAS and OMIM information together (Figure 4b, right panel).
Discussion
In this paper, we have shown that uKIN, a network propagation method that incorporates both existing
knowledge as well as new information, is a highly effective and versatile approach for uncovering disease
genes. Our method is based upon the intuition that prior knowledge of disease-relevant genes can be used
to guide the way information from new data is spread and interpreted in the context of biological networks.
Because uKIN uses prior knowledge, it has higher precision than other state-of-the-art methods in detecting
known cancer genes. Further, it excels at highlighting infrequently mutated genes that are nevertheless
relevant for cancer. Additionally, we have shown that uKIN can be applied to discover genes relevant for
other complex diseases as well.
The framework presented here can be extended in a number of natural ways. First, in addition to positive
knowledge of known disease genes, we may also have “negative” knowledge of genes that are not involved
in the development of a given disease. These genes can propagate their “negative” information, thereby
biasing the random walk to move away from their respective modules and perhaps further enhancing the
performance of our method. Second, uKIN is likely to benefit from incorporating edge weights that reflect
the reliability of interactions between proteins; these weights will have an impact on both the propagation
of prior knowledge as well as the guided random walks. Third, since a recent study [52] has shown that
contrasting cancer mutation data with natural germline variation data helps boost the true disease signal by
downgrading genes that vary frequently in nature, uKIN’s performance may benefit from scaling the start-
ing probabilities of the new putatively implicated genes to account for their variation in healthy populations.
Fourth, while here we have demonstrated how uKIN can use cancer-type specific knowledge, cancers of the
same type can often be grouped into distinct subtypes, and such highly-detailed knowledge may improve
uKIN’s performance even further. Finally, we note that network propagation approaches have been applied
to non-disease settings as well, including biological process prediction [53, 54]. We conjecture that our
guided network propagation approach will additionally be useful in other scenarios in computational biol-
ogy, including where new data (e.g., arising from functional genomics screens) need to be interpreted in the
context of what is already known about a biological process of interest.
In conclusion, uKIN is a flexible and effective method that handles diverse types of new information.
As our knowledge of disease-associated genes continues to grow and be refined, and as new experimental
data becomes more abundant, we expect that the power of uKIN for accurately prioritizing disease genes
will continue to increase.
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Supplementary Figures and Tables
The following pages contain 1 table and 4 supplementary figures that support the findings of the main paper.
14
Cancer Number	of 								Number	of	Mutated	Genes
Symbol Cancer	Type Patients Total Average Cut	off	
ACC Adrenocortical	carcinoma 76 2068 32.1 80
BLCA Bladder	Urothelial	Carcinoma 196 11407 135.7 300
BRCA Breast	invasive	carcinoma 882 10813 27 80
CESC
Cervical	squamous	cell	carcinoma	and	
endocervical	adenocarcinoma 173 6907 63 200
COAD Colon	adenocarcinoma 153 6521 74.4 150
GBM Glioblastoma	multiforme 278 7250 46.8 80
HNSC Head	and	Neck	squamous	cell	carcinoma 435 13048 87.9 200
KICH Kidney	Chromophobe 64 661 11 50
KIRC Kidney	renal	clear	cell	carcinoma 416 9212 40.9 100
KIRP Kidney	renal	papillary	cell	carcinoma 166 5687 47.7 100
LGG Brain	Lower	Grade	Glioma 451 7130 28.8 60
LIHC Liver	hepatocellular	carcinoma 196 7705 67.3 200
LUAD Lung	adenocarcinoma 487 15481 172.8 500
LUSC Lung	squamous	cell	carcinoma 167 12264 212 500
OV Ovarian	serous	cystadenocarcinoma 138 3390 30.7 80
PAAD Pancreatic	adenocarcinoma 124 3228 36.8 100
PCPG Pheochromocytoma	and	Paraganglioma 183 1819 11.7 30
PRAD Prostate	adenocarcinoma 238 4792 28.1 50
READ Rectum	adenocarcinoma 34 1214 40.7 150
SKCM Skin	Cutaneous	Melanoma 329 14748 240.1 1000
STAD Stomach	adenocarcinoma 242 10595 103.5 500
THCA Thyroid	carcinoma 401 2268 7.4 30
UCEC Uterine	Corpus	Endometrial	Carcinoma 155 4282 38.8 100
UCS Uterine	Carcinosarcoma 54 1787 38.9 80
Table S1: TCGA dataset and statistics. We list the 24 cancer types studied along with their abbreviations.
For each cancer type, we give the total number of patient samples considered after highly mutated samples
are filtered out, the total number of mutated genes across these samples, the average number of mutated
genes across all samples, and the cutoff on the number of mutated genes within a sample that was used to
filter samples.
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Figure S1: Comparison between uKIN and Hotnet2. For each cancer type, we compute the precision
and recall of the genes returned by uKIN with α=0.5 and Hotnet2. Hotnet2 is run with default parame-
ters (100 permuted networks, and β = 0.2 for the restart probability for the insulated heat diffusion process).
Hotnet2 outputs a set of genes predicted to be cancer-relevant, and these genes are not ranked. Thus,
for uKIN, we consider the same number of top scoring genes as output by Hotnet2. uKIN exhibits both
higher precision and higher recall than Hotnet2 across all 24 cancer types.
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Figure S2: Robustness of uKIN. (a) To make sure that the results reported for uKIN in Figures 2 and 3 are
robust with respect to the set of labelled cancer genes H, instead of randomly sampling 400 genes from the
Cancer Gene Census (CGC) list, we formH using genes from other sources. Specifically, we aggregate the
cancer genes provided by Hofree et al. in [55] (which they obtained by querying the UniprotKB database for
the keyword-terms ‘proto-oncogene,’ ‘oncogene’ and ‘tumoursuppressor’ gene) and Vogelstein et al. [56],
excluding any genes present in the set of prior knowledge K. Log-fold AUPRCs are computed as described
in the main text. The results are consistent with those shown in Figures 2 and 3 based on the CGC list and
show the superior performance of uKIN as compared to the other methods in recapitulating known cancer
genes. (b) To make sure that the results reported for uKIN in Figures 2 and 3 are robust with respect to
number of genes used in evaluation, we compute AUPRCs using the top 50 predicted genes. The results
are consistent with those shown in Figures 2 and 3 which use the top 100 predicted genes, and show the
superior performance of uKIN as compared to the baselines and other methods in recapitulating known
cancer genes. The results are also consistent when computing AUPRC’s using 150 genes (data not shown).
(c) To make sure that our method is robust with respect to the specific network utilized, we repeat our entire
analysis procedure for uKIN with α = 0.5 using the Biogrid network. The results are consistent with those
shown in Figures 2 and 3, based on the HPRD network. (d) To make sure our method utilizes network
structure appropriately, we also consider performance of uKIN on the real HPRD network as compared
to randomized HPRD networks. In the left panel, we use a node label shuffling randomization where the
network structure is maintained but gene names are swapped (thereby genes can have very different numbers
of interactions in the randomizations). In the right panel, we use a classic degree-preserving randomization
(edge swapping). For each of the 24 cancers, we compute the log2 ratio of the area under the precision recall
curve using uKIN with α = 0.5 on the real network and on the randomized network and show the average
over 10 different randomizations. Performance, as expected, is worse for both randomizations across all
cancers. We note that significant cancer-relevant information is retained in these randomized networks. In
particular, in both types of network randomizations, we maintain the relationships between genes and the
samples that they are found to be somatically mutated in. Thus, some highly mutated CGC genes may still
be output by uKIN when running on randomized networks.
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Figure S3: (a) uKIN benefits from more knowledge. As we consider larger numbers of genes comprising
the set of prior knowledge (|K| = 5, 10, 20, 40, . . . , 100), we examine the ability of uKIN to uncover CGC
genes in the same fixed setH when using α = 0.5 (blue triangles), α = 0.3 (pink circles) or α = 0 (orange
squares). uKIN is run on the HPRD network with the kidney renal clear cell carcinoma (KIRC) dataset.
We show the log2 ratio, averaged over 100 runs, of the AUPRC of each version of uKIN to the AUPRC
for α = 1 which is constant across all possible K (and corresponds to the case where genes are ranked by
mutational frequency). For small K, α = 0 performs poorly as is expected; as the prior knowledge available
increases so does the performance. For both α = 0.3 and α = 0.5, an increase in the size of K leads to
an initial increase in the performance but eventually performance plateaus. When limited prior knowledge
is available (|K| < 20), α = 0.5, which uses more of the new information, does better then α = 0.3,
which relies more on using prior knowledge. When prior knowledge is abundant (|K| > 40), uKIN with
α = 0.3 outperforms α = 0.5. As the number of genes comprising the set of prior knowledge increases,
spreading information just from those genes (α = 0) improves in performance. This is consistent with
the observed clustering of CGC genes within biological networks [20]. However, even when propagating
information from 100 known cancer genes, the performance is worse than that when integrating it with
new information (with either α = 0.3 or α = 0.5, Figure 3a). (b) uKIN is robust to small amounts of
erroneous knowledge. We replace a fraction of the CGCs in the set of prior knowledge genes K with non-
cancerous genes chosen uniformly at random from the set of non-CGC genes in the network. We consider
the performance for uKIN with α = 0 and α = 0.5 when 0%, 10%, 20% and 30% of the prior knowledge
genes are replaced with non-cancer genes. 100 randomizations are performed at each level of incorrect
knowledge. For each run, performance is measured as the log2 ratio of the AUPRC of uKIN (with either
α = 0 or α = 0.5) to the AUPRC for the case where uKIN is run with α = 1 (which is constant). uKIN is
run on the HPRD network with KIRC dataset with 20 CGC genes comprising the prior knowledge. Violin
plots of this measure are shown are shown for α = 0 (orange) and α = 0.5 (blue), jittered around the 0%,
10%, 20% and 30% tick marks. At α = 0.5, while performance steadily decreases, uKIN remains robust to
some incorrect knowledge (≤ 20%). As expected, for α = 0, the decrease is more notable even when 10%
of the prior knowledge is incorrect because in that case uKIN uses only prior knowledge.
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Figure S4: uKIN identifies rarely mutated genes. To illustrate uKIN’s ability to predict genes as cancer-
relevant cancer even if they are mutated across fewer numbers of individuals, we consider mutation rates of
uKIN’s top scoring genes. For each cancer type, we run uKIN 100 times with α = 0.5 and 20 genes as prior
knowledge (see Methods). For each gene, its final score is obtained by averaging its scores (arising from the
stationary distributions) across the runs; if a gene is in the set of prior knowledge genes K for a run, this run
is not considered for its final score. For each of the 100 genes with highest final scores, we consider the rank
of its mutation rate (y-axis). The mutation rate of a gene is computed as the number of observed somatic
missense and nonsense mutations across tumors of that cancer type, divided by the number of amino acids
in the encoded protein. Then, for each cancer type, genes are ranked by mutation rate where the gene with
the highest mutation rate is given the lowest rank. Known CGC genes are in red and novel predictions in
blue. The top predictions consist of many heavily mutated genes (i.e., those with low ranks), but uKIN is
also able to uncover known cancer genes with very low mutational ranks (red dots towards the top).
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